Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.

Slides:



Advertisements
Similar presentations
1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.
Advertisements

Hepatitis C in the UK 2014 report. Figure 1: Trend in anti-HCV prevalence* among people who inject drugs in England: Hepatitis C in the UK.
Dr John Dillon NHS Tayside Brian Stephens NHS Tayside Jan Tait NHS Tayside Daniel Kelly CAIR Scotland Ingrid Hainey CAIR Scotland Mike Burns CAIR Scotland.
Scotland’s Hepatitis C Action Plan, a patient approach?
Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.
Needs Assessment of Hepatitis C Testing, Treatment and Support Services: Survey of Laboratories in Scotland Undertaking Hepatitis C Testing.
Mobile clinics: How to improve access to health in remote areas? WHO Informal Technical Consultation BRAVE Geneva 6-7 November 2012 Dr Charles Senessie.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2011.
Hepatitis C Disease & Treatment.
H EALTH INEQUALITIES IN THE NEW EU MEMBER STATES AND CANDIDATE COUNTRIES.
National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007.
Unmet Need for Hepatitis C PCR Testing, New York City, Emily McGibbon, MPH June 2011 CSTE Annual Conference.
Wyoming Department of Health Communicable Diseases
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
HEPATITIS C TREATMENT EXPANSION INITIATIVE ETAC Project Summary Webinar May 28, 2014 The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
Testing, Treatment, Care and Support Draft Actions for Phase II.
Are hip fracture rates falling or rising over time? Using routine data to understand the Epidemiology. Scottish Faculty of Public Health Annual Conference,
Hepatitis C Testing in the Muslim Community Hasnain Jafferbhoy Grampian Hepatitis Stakeholder Conference 16 th June 2011.
HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Network Update Cathy Young Managed Care Network Manager 16 th June 2011.
Needs Assessment of Hepatitis C Testing, Treatment and Support Services: Survey of General Practitioners in Primary Care.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
TREATMENT TIME GUARANTEE M Brown May Aims of the session TTG and its Waiting Times context Measurement –Reasonable offer –Impact of Board decisions.
Joan Blackwood Clinical Lead MH Service Re-design Frances Paton Business Intelligence Manager (Partnerships) Fiona McMahon Senior Practitioner, Re-admissions/Service.
National Mental Health Programme Dr Stella Clark Clinical Lead for Mental Health NHS 24 Cathy Dorrian Service Development Manager Scottish Centre for Telehealth.
Senior Drug Users: Scotland April Shaw & Austin Smith November 2009.
Hepatitis C RSP Guidance 2016/17 In 2015/16, implementation began on a revised approach to the delivery of hepatitis C services Resources directed towards.
Acknowledgements Natalie Weir, for help with the charts. Conclusion Toxicities were broadly as expected and interestingly, most care issues were associated.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
QUALITY INDICATORS FOR HEPATITIS C Michele Hilton Boon Ray Fox, Clare Echlin, Scott Horton, Hepatitis C Project Group.
Data and Audit Working Group Ciara McColgan Consultant Paediatrician Greater Glasgow and Clyde.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
Hep C clinic Jessie Anderson, Cathy Scott, Kim Macbeth, Dave Findlay and John Budd Edinburgh Access Practice.
Karyn Kaplan Thai AIDS Treatment Action Group (TTAG)
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
What is the contribution of alcohol to liver disease in the hepatitis C infected population. The epidemiological evidence Hamish Innes Research Fellow.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Jana Feldmane Ministry of Health of Latvia Public Health Department Health care overview in prisons.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: Annual Surveillance Report 2016.
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
Cascade of care for persons newly diagnosed
Hepatitis B and C management pathways in prison:
Department of Veterans Affairs
A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection 
Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people Annual Surveillance Report 2017.
Expanding the Universe of Viral Hepatitis Treaters
History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
More Than Treatment.
NHS Grampian Annual Review
Just when you thought you knew everything.
Yasuhiko Sugawara, Masatoshi Makuuchi 
Hepatitis C: After the Diagnosis
Hepatitis C treatment in patients with kidney disease
Professor Jack Lambert
Hepatitis C Testing, Treatment, Care and Support
Hepatitis C case-finding – An opportunity for community pharmacy
Presentation transcript:

Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases

Key questions 1.How many people have been diagnosed with HCV in Scotland? 2.How many people have attended a clinic for HCV treatment/care? 3.How many people have been initiated on HCV antiviral therapy? 4.How many patients have cleared HCV from antiviral therapy?

1.How many people have been diagnosed with HCV in Scotland?

Annual and cumulative HCV diagnoses in Scotland (to 2006)

Characteristics of HCV diagnosed persons in Scotland ( , N = 6442) 66% male 22%  40 years at diagnosis; mean age = 34 90% current/former injecting drug users 55% genotype 2/3 50% of referrals were from hospitals, 24% from GPs, 6% GUM, 3% prisons

Cumulative HCV diagnoses by NHS Board in Scotland (to 2006) Lothian 14% Tayside 7% Grampian 12% Greater Glasgow & Clyde 41% N = 22,073 0– – – –

1.How many people have been diagnosed with HCV in Scotland? 2.How many people have attended a clinic for HCV treatment/care?

0– – – – Locations of 16 HCV treatment/care centres Treatment centre N = 22,073 Number of diagnoses

Locations of HCV treatment/care centres in relation to the HCV diagnosed population Mean drive-time of 20 min. from HCV diagnosed person’s place of residence (postcode district) to the nearest HCV treatment/care centre. (range min. for NHS Boards in mainland Scotland)

Numbers of diagnosed HCV attending HCV treatment/care centres (to 2006) Diagnosed HCV antibody positive:22,073 Diagnosed with chronic HCV (est.):16,500 Attended specialist services for chronic HCV (est.):9,000 Diagnosed with chronic HCV (est.):14,500 Ever chronic HCV and ever attended specialist services (est.): 8,000 Approximately 55% of persons living with diagnosed chronic HCV have ever been in specialist care Living + dead Living

New attendees at HCV treatment/care centres ( , 5 clinics, N = 1202) 70% male 38%  40 years at first attendance; mean age = 38 78% current/former injecting drug users 52% of referrals were from hospitals, 28% from GPs 92% PCR positive

New attendees at HCV treatment/care centres ( , 5 clinics, N = 1677) : 73% increase in new patients (range %, 5 clinics)

Follow-up of new patients attending HCV treatment/care centres ( , 5 clinics, N = 964) Assessed for Rx 57% (32-70%) New attendees N=964 Not assessed for Rx 43% Most common reason is failure to attend

Follow-up of new patients attending HCV treatment/care centres ( , 5 clinics, N = 964) Assessed for Rx 57% (32-70%) New attendees N=964 Not assessed for Rx 43% Not suitable for Rx 32% (17-76%) Most frequent: ongoing IDU chaotic lifestyle

Follow-up of new patients attending HCV treatment/care centres ( , 5 clinics, N = 964) Assessed for Rx 57% (32-70%) New attendees N=964 Not assessed for Rx 43% Suitable for Rx 68% (23-82%) Approximately 20% refused or deferred the offer

Follow-up of new patients attending HCV treatment/care centres ( , 5 clinics, N = 964) Assessed for Rx 57% (32-70%) New attendees N=964 Not assessed for Rx 43% Suitable for Rx 68% (23-82%) Approximately 30% of new attendees began therapy Not suitable for Rx 32% (17-76%)

1.How many people have been diagnosed with HCV in Scotland? 2.How many people have attended a clinic for HCV treatment/care? 3.How many people have been initiated on HCV antiviral therapy?

Numbers of HCV diagnosed persons initiated on antiviral therapy (to 2006) Diagnosed HCV antibody positive:22,073 Diagnosed with chronic HCV (est.):16,500 Attended specialist services for chronic HCV (est.):9,000 Initiated on antiviral therapy (est.): 2,300 Living + dead Approximately 14% of persons who have ever been diagnosed with chronic HCV have been initiated on antiviral therapy

Patients initiated on HCV antiviral therapy ( , 5 clinics, N = 353) 71% male 57%  40 years at initiation; mean age = 41 56% injecting drug users 62% genotype 2/3 12% known to have cirrhosis 92% pegylated interferon +/- ribavirin

Patients initiated on HCV antiviral therapy ( , 5 clinics, N = 678) 2000/1 to 2004/5: 117% increase in number of patients initiating therapy (range %, 5 clinics)

Key questions 1.How many people have been diagnosed with HCV in Scotland? 2.How many people have attended a clinic for HCV treatment/care? 3.How many people have been initiated on HCV antiviral therapy? 4.How many patients have cleared HCV from antiviral therapy?

Response to antiviral therapy ( , 5 clinics, N = 286) 46% sustained viral response 43% no sustained viral response 11% incomplete –major side effect: 52% –patient request: 30% –other: 18%

Current capacity of HCV treatment/care centres (2006) Number of patients attending HCV treatment/care centres in 2006:4,000 Number of patients initiated on antiviral therapy in 2006 (est.):450 Number of patients currently on waiting list for therapy (est.):330

Summary Estimated that 55% of people living with chronic HCV have ever attended specialist services Estimated that 14% of those with diagnosed HCV have ever initiated therapy Annual numbers of new attendances and therapy initiations are increasing Low completion of assessment (57%) is an impediment to treatment